Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants

References

• Hall CB. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med.344, 1917–1928 (2001).
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA282, 1440–1446 (1999).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Taber LH, Frank AL, Kasel JH. Risk of primary infection and reinfection with respiratory-syncytial virus. AJDC140, 543–546 (1986).
   PubMedGoogle Scholar
• Simoes EAF. Respiratory syncytial virus infection. Lancet354, 847–852 (1999).
   PubMed Web of Science ®Google Scholar
• Arnold SR, Wang EE, Law BJ et al.; Pediatric Investigators Collaborative Network on Infections in Canada. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr. Infect. Dis. J.18, 866–869 (1999).
   PubMed Web of Science ®Google Scholar
• Wilkesmann A, Ammann RA, Schildgen O et al.; the DSM RSV Ped Study Group. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course, Pediatr. Infect. Dis. J.26, 485–491 (2007).
   PubMed Web of Science ®Google Scholar
• Meert K, Heidemann S, Abella B, Saeniak A. Does prematurity alter the course of respiratory syncytial virus infection? Crit. Care Med.18, 1357–1359 (1990).
   PubMed Web of Science ®Google Scholar
• Kristensen K, Dahm T, Frederiksen PS et al. Epidemiology of respiratory syncytial virus infection requiring hospitalisation in East Denmark. Pediatr. Infect. Dis. J.17, 996–1000 (1998).
   PubMed Web of Science ®Google Scholar
• Resch B, Gusenleitner W, Müller W. The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection30, 193–197 (2002).
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial virus infection in infants with congenital heart disease. N. Engl. J. Med.307, 397–400 (1982).
   PubMed Web of Science ®Google Scholar
• Navas L, Wang EEL, de Carvalho V, Robinson J; the PICNIC study group. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalised population of Canadian children. J. Pediatr.121, 348–354 (1992).
   PubMed Web of Science ®Google Scholar
• Altman CA, Englund JA, Demmler G et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of pre-operative screening. Pediatr. Cardiol.21, 433–438 (2000).
   PubMed Web of Science ®Google Scholar
• Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J. Pediatr.143, S150–S156 (2003).
   PubMed Web of Science ®Google Scholar
• Chevret L, Mbieleu B, Essouri S, Durand P, Chevret S, Devictor D. Bronchiolitis treated with mechanical ventilation: prognosis factor and outcome in a series of 135 children. Arch. Pediatr.12, 385–390 (2005).
   Google Scholar
• Sigurs N, Gustafsson PM, Bjarnason R et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med.171, 137–141 (2005).
   PubMed Web of Science ®Google Scholar
• Korppi M, Piippo-Savolainen E, Korhonen K, Remes S. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr. Pulmonol.38, 155–160 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson S, Oliver C, Prince GA et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis.176, 1215–1224 (1997).
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Hall CB, Kimberlin DW et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J. Infect. Dis.190(5), 975–978 (2004)
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Aitken J, Harrison L. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. J. Pediatr.143, 123–126 (2003).
   Google Scholar
• Malley R, DeVincenzo J, Ramilo O et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis.178, 1555–1561 (1998).
   PubMed Web of Science ®Google Scholar
• Subramanian KNS, Weisman LE, Rhodes T et al.; the MEDI-493 Study group. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J.17, 110–115 (1998).
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics102, 531–537 (1998).
   PubMed Web of Science ®Google Scholar
• American Academy of Paediatrics. Prevention of respiratory syncytial virus infections: indications for use of of palivizumab and update on the use of RSV-IGIV. Paediatrics102, 1211–1216 (1998).
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner C et al. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr.143, 532–540 (2003).
   PubMed Web of Science ®Google Scholar
• American Academy of Paediatrics. Revised indications for the use of palivizumab and RSV-IGIV for the prevention of respiratory syncytial virus infection. Pediatrics112, 1442–1452 (2003).
   PubMed Web of Science ®Google Scholar
• Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 and 1999 respiratory syncytial virus season: the Palivizumab Outcomes Study Group. Pediatr. Infect. Dis. J.19 (11), 1068–1071 (2000).
   PubMed Web of Science ®Google Scholar
• Parnes C, Guillermin J, Habersang R et al.; Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from The Palivizumab Outcomes Registry. Pediatr. Pulmonol.35(6), 484–489 (2003).
   PubMed Web of Science ®Google Scholar
• Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr. Infect. Dis. J.22(2 Suppl.), S46–S54 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen SA, Zanni R, Cohen A, Harrington M, Van Veldhuisen P. Palivizumab use in subjects with congenital heart disease: results from the 2000–2004 palivizumab outcomes registry. Pediatr. Cardiol.29(2), 382–387 (2008).
   PubMed Web of Science ®Google Scholar
• Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: a “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr. Pulmonol.41, 1167–1174 (2006).
   PubMed Web of Science ®Google Scholar
• Simoes EAF, Groothuis JR, Carbonell-Estrany X et al.; the Palivizumab Long-Term Respiratory Outcomes Study Group. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr.151, 34–42 (2007).
   PubMed Web of Science ®Google Scholar
• Matza LS, Swensen AR, Flood EM, Secnik K, Leidy NK. Assessment of health-related quality of life in children: a review of conceptual, methodological, and regulatory issues. Value Health7(1), 79–92 (2004).
   PubMed Web of Science ®Google Scholar
• Leader S, Jacobson P, Marcin J, Vardis R, Sorrentino M, Murray D. A method for identifying the financial burden of hospitalized infants on families. Value Health5(1), 55–59 (2002).
   Google Scholar
• Leader S, Yang H, DeVicenzo J, Jacobson P, Marcin J, Murray D. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants. Value Health6(2), 100–106 (2003).
   PubMed Web of Science ®Google Scholar
• Greenough A, Cox S, Alexander J et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch. Dis. Child.55, 463–468 (2001).
   Google Scholar
• Greenough A, Alexander J, Burgess S et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch. Dis. Child.89, 673–678 (2004).
   PubMed Web of Science ®Google Scholar
• Broughton S, Roberts A, Fox G et al. Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax60, 1039–1044 (2005).
   PubMed Web of Science ®Google Scholar
• Howard TS, Hoffman LH, Stang PE, Simoes EAF. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J. Pediatr.137, 227–232 (2000).
   PubMed Web of Science ®Google Scholar
• Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics22(5), 275–284 (2004).
   PubMed Web of Science ®Google Scholar
• Langley JM, Wang EE, Law BJ et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J. Pediatr.131(1), 113–117 (1997).
   PubMed Web of Science ®Google Scholar
• Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J. Pediatr.143, S133–S141 (2003).
   Google Scholar
• Chan PWK, Abdel-Latif MEA. Cost of hospitalisation for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. Acta Paediatr.92, 481–485 (2003).
   PubMed Web of Science ®Google Scholar
• Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost–effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics.104(3), 419–427 (1999).
   PubMed Web of Science ®Google Scholar
• Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin. Ther.21(4), 752–766 (1999).
   PubMedGoogle Scholar
• Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis. Arch. Pediatr. Adolesc. Med.154(1), 55–61 (2000).
   PubMed Web of Science ®Google Scholar
• Numa A. Outcome of respiratory syncytial virus infection and a cost –benefit analysis of prophylaxis. J. Paediatr. Child Health36(5), 422–427 (2000).
   PubMedGoogle Scholar
• Lofland JH, O’Connor JP, Chatterton ML et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost–effectiveness analysis. Clin. Ther.22(11), 1357–1369 (2000).
   PubMed Web of Science ®Google Scholar
• Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants – implications for use of RSV immune globulin. Arch. Dis. Child.83(2), 122–127 (2000).
   PubMed Web of Science ®Google Scholar
• Clark SJ, Beresford MW, Subhedat NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch. Dis. Child.83(4), 313–316 (2000).
   PubMed Web of Science ®Google Scholar
• Duppenthaler A, Gorgievski-Hrisoho M, Aebi C. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Swiss Med. Wkly131, 146–151 (2001).
   Google Scholar
• Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH. A cost–benefit analysis of RSV prophylaxis in high-risk infants. Ann. Pharmacother.35(10), 1186–1193 (2001).
   Web of Science ®Google Scholar
• Barton LL, Grant KL, Lemen RJ. Respiratory syncytial virus immune globulin: decisions and costs. Pediatr. Pulmonol.32(1), 20–28 (2001).
   Google Scholar
• Jacquemot L, Catelin C, Dobrzynski M, de Parscau L, Sizun J. Prevention of community-acquired respiratory syncytial virus infections in premature infants: cost–benefit evaluation in the Finistère Department. Arch. Pediatr.9(2), 219–221 (2002).
   Google Scholar
• Shireman TI, Braman KS. Impact and cost–effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid’s high-risk children. Arch. Pediatr. Adolesc. Med.156(12), 1251–1255 (2002).
   PubMed Web of Science ®Google Scholar
• McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr. Pulmonol.34, 262–266 (2002).
   PubMed Web of Science ®Google Scholar
• Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, Graham D, Grimwood K, Pattemore PK, Schousboe M. Cost–effectiveness of palivizumab in New Zealand. J. Paediatr. Child Health38(4), 352–357 (2002).
   PubMed Web of Science ®Google Scholar
• Fariña D, Rodríguez SP, Bauer G et al. Respiratory syncytial virus prophylaxis: cost–effective analysis in Argentina. Pediatr. Infect. Dis. J.21(4), 287–291 (2002).
   PubMed Web of Science ®Google Scholar
• Vogel AM, Lennon DR, Broadbent R et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J. Paediatr. Child Health38(6), 550–554 (2002).
   PubMed Web of Science ®Google Scholar
• Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch. Pediatr. Adolesc. Med.156(10), 1034–1041 (2002).
   PubMed Web of Science ®Google Scholar
• Zaw W, McDonald J. Respiratory syncytial virus bronchiolitis in ex-preterm infants in the Scottish highlands: review of hospital admissions and an analysis of hospital cost. Scott. Med. J.48(4), 108–110 (2003).
   Google Scholar
• Strutton DR, Stang PE. Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making. J. Pediatr.143(5 Suppl.), S157–S162 (2003)
   Web of Science ®Google Scholar
• Lapeña López de Armentia S, Robles García MB, Martínez Badás JP et al. Potential impact and cost-efficacy of bronchiolitis prophylaxis with palivizumab in preterm infants with a gestational age of less than 33 weeks. An. Pediatr. (Barc.)59(4), 328–333 (2003).
   Google Scholar
• Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch. Dis. Child.88(12), 1065–1069 (2003).
   PubMed Web of Science ®Google Scholar
• Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur. J. Pediatr.162(4), 237–244 (2003).
   PubMed Web of Science ®Google Scholar
• Wegner S, Vann JJ, Liu G et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics114(6), 1612–1619 (2004).
   PubMed Web of Science ®Google Scholar
• Rietveld E, De Jonge HC, Polder JJ et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr. Infect. Dis. J.23(6), 523–529 (2004).
   PubMed Web of Science ®Google Scholar
• Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics114(6), 1606–1611 (2004).
   PubMed Web of Science ®Google Scholar
• Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol. Young15(3), 251–255 (2005).
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Valkonen H, Lehtonen L, Vainionpaa R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch. Dis. Child. Fetal Neonatal Ed.90(1), F64–F68 (2005).
   PubMedGoogle Scholar
• Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E et al. The efficiency (cost–effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32–35 weeks in Spain. Ann. Pediatr. (Barc.)65(4), 316–324 (2006).
   PubMedGoogle Scholar
• Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost–effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch. Pediatr. Adolesc. Med.160(10), 1070–1076 (2006).
   PubMed Web of Science ®Google Scholar
• Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects – hospitalizations and costs. Acta Paediatr.95(4), 404–406 (2006).
   PubMed Web of Science ®Google Scholar
• Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F. Cost–effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J. Paediatr. Child Health42(5), 253–258 (2006).
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Wittenberg W, Lebmeier M. Cost–effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics25(1), 55–71 (2007).
   PubMed Web of Science ®Google Scholar
• Embleton ND, Dharmaraj ST, Deshpande S. Cost–effectiveness of palivizumab in infancy. Expert Rev. Pharmaeconomics Outcomes Res.7(5), 445–458 (2007).
   Google Scholar
• Resch B, Gusenleitner W, Nuijten MJC, Lebmeier M, Wittenberg W. Cost–effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin. Ther.30(4), 749–760 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez SP, Farina D, Bauer G. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost–effectiveness analysis. Pediatr. Infect. Dis. J.27(7), 660–661 (2008).
   PubMed Web of Science ®Google Scholar
• Moler FW. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure? Pediatrics104, 559–560 (1999).
   Google Scholar
• Groothuis JR. The pitfalls of using managed care databases in cost–effectiveness research. Pediatrics104, 1124–1125 (1999).
   PubMed Web of Science ®Google Scholar
• Eppes SC. Questions about palivizumab (Synagis). Pediatrics103(2), 534–535; Author reply 535–536 (1999).
   Google Scholar
• Moler FW, Brown RW, Faix RG, Gilsdorf JR. Comments on palivizumab (Synagis). Pediatrics103, 495–497 (1999).
   Google Scholar
• Seeler RA, Schatz B. Palivizumab (Synagis) – cohorting babies to reduce waste. Pediatrics104, 1170–1171 (1999).
   Google Scholar
• Carter BS. Palivizumab (synagis): counting “costs” and values. Pediatrics106, 533–534 (2000).
   Google Scholar
• Smith RA, Boon R. Economic disadvantages of palivizumab. Arch. Dis. Child.82(4), 336 (2000).
   Google Scholar
• Deshpande S. RSV prevention. Arch. Dis. Child.82(1), 88 (2000).
   Google Scholar
• Moler F. Cost estimates of prophylaxis. Arch. Pediatr. Adolesc. Med.155(2), 199–200 (2001).
   Google Scholar
• Greisen G. Is it smart to give immunoglobulin prophylaxis against respiratory syncytial virus infection? Ugeskr. Laeger.163(47), 6607 (2001).
   Google Scholar
• Robbins JM, Tilford JM, Jacobs RJ, Wheeler JG, Gillaspy SR, Schutze GE. Costs and respiratory syncytial virus. Pediatrics107(3), 608–609 (2001).
   Google Scholar
• Zaaijer HL, Vandenbroucke-Grauls CM, Franssen EJ. Optimum dosage regimen of palivizumab? Ther. Drug Monit.24(3), 444–445 (2002).
   Google Scholar
• Silverman W. A health care management company’s experience with palivizumab. Manag. Care11(1), 45–46. (2002).
   Google Scholar
• Vergouwe Y, Steyerberg EW, Rietveld E, Moll HA. Comment: prophylaxis for RSV hospitalization may not be cost-saving. Ann. Pharmacother.36(3), 534–535 (2002).
   Google Scholar
• Klassen TB. Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion? Arch. Pediatr. Adolesc. Med.156(12), 1180–1181 (2002).
   Google Scholar
• Suresh S, Schilling S, Dakin C, Harris MA. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution. J. Paediatr. Child Health39(8), 637 (2003).
   Google Scholar
• Helm EA, Cummings GE, Keane V, King JC Jr. Administration of palivizumab: a medical provider’s perspective. Clin. Pediatr. (Phila.)42(9), 821–826 (2003).
   PubMed Web of Science ®Google Scholar
• Marks AS. Indirect costs of respiratory syncytial virus hospitalizations: a commentary. Value Health6(2), 98–99 (2003).
   Google Scholar
• Stevens TP, Hall CB. Controversies in palivizumab use. Pediatr. Infect. Dis. J.23(11), 1051–1052 (2004).
   PubMedGoogle Scholar
• Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infants. Is it worth it? Arch. Dis. Child. Fetal Neonatal Ed.90(4), F286–F289 (2005).
   PubMedGoogle Scholar
• Bala P, Ryan CA, Murphy BP. Hospital admissions for bronchiolitis in preterm infants in the absence of respiratory syncytial virus prophylaxis. Arch. Dis. Child. Fetal Neonatal Ed.90(1), F92 (2005).
   Web of Science ®Google Scholar
• Van Rostenberghe HLA, Kew ST, Hanifah MJM. RSV and bronchiolitis. Arch. Dis. Child. Fetal Neonatal Ed.91(2), F154 (2006).
   Google Scholar
• Sunnegårdh J. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease – who should receive it? Acta Paediatr.95(4), 388–390 (2006).
   Google Scholar
• Mahadevia PJ, Malinoski FJ. Cost–effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab. Arch. Pediatr. Adolesc. Med.161, 519–520 (2007).
   Google Scholar
• Sorbero MES, ElHassan NO, Hall CB, Stevens TP, Dick AW. Cost–effectiveness of respiratory syncytial virus prophylaxis with palivizumab – reply. Arch. Pediatr. Adolesc. Med.161, 520 (2007).
   Google Scholar
• Grosse SD. Assessing cost–effectiveness in healthcare: history of the US$50,000 per QALY threshold. Expert Rev. Pharmaeconomics Outcomes Res.8(2), 165–178 (2008).
   PubMedGoogle Scholar
• Mauskopf J, Rutten F, Schonfeld W. Cost–effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics21(14), 991–1000 (2003).
   PubMed Web of Science ®Google Scholar
• Goldman L, Garber AM, Grover SA, Hlatky MA; Task force 6. Cost effectiveness of assessment and management of risk factors. JACC27(5), 964–1030 (1996).
   Google Scholar
• Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J. Pediatr.113, 826–830 (1988).
   PubMed Web of Science ®Google Scholar
• Garcia DF, Hiatt PW, Jewell A et al. Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediatr. Pulmonol.42, 66–74 (2007).
   PubMed Web of Science ®Google Scholar
• Madhi SA, Schoub B, Simmank K, Blackburn N, Klugmann KP. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J. Pediatr.137, 78–84 (2000).
   PubMed Web of Science ®Google Scholar
• Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial virus infection in children with compromised immune function. N. Engl. J. Med.315, 77–81 (1986).
   PubMed Web of Science ®Google Scholar
• Millner ME, de la Monte SM, Hutchins GM. Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndromes. Am. J. Dis. Child.139, 1111–1114 (1985).
   Google Scholar
• Schneider S, Borzy MS. Fatal respiratory syncytial virus pneumonia as the presenting feature of severe combined immunodeficiency disease. Clin. Pediatr. (Phila.)35, 147–149 (1996).
   Google Scholar
• King JC Jr, Burke AR, Clemens JD et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr. Infect. Dis. J.12, 733–739 (1993).
   Google Scholar
• Resch B, Berger A, Bernert G et al. Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwegserkrankung. Monatsschr. Kinderheilkd156, 381–383 (2008).
   Google Scholar
• Mejias A, Chavez-Bueno S, Rios AM et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob. Agents Chemother.49, 4700–4707 (2005).
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory sncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol.368, 652–665 (2007).
   PubMed Web of Science ®Google Scholar
• Goldman L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term β-adrenergic antagonists after acute myocardial infarction. N. Engl. J. Med.319, 152–157 (1988).
   PubMed Web of Science ®Google Scholar
• Asensi F, De Jose M, Lorente M et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health7(1), 36–51 (2004).
   PubMed Web of Science ®Google Scholar